SNCA

Alpha-synuclein · P37840 · SNCA on Sugi Atlas →

118,772 patent compounds predicted against SNCA, 85,603 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL64975 SCHEMBL64975 0.50 8/20
Hydromethylthionine Hydromethylthionine (SCHEMBL109756) 0.50 8/20
SCHEMBL109009 SCHEMBL109009 0.65 6/20
SCHEMBL124411 SCHEMBL124411 0.46 6/20
Catechin Catechin (SCHEMBL19411) 1.00 5/20
(-)-Epicatechin (-)-Epicatechin (SCHEMBL19412) 1.00 5/20
Cianidanol Cianidanol (SCHEMBL19741) 1.00 5/20
Cianidanol Cianidanol (SCHEMBL133974) 0.97 5/20
Catechin Catechin (SCHEMBL133975) 0.97 5/20
Protizinic Acid Protizinic Acid (SCHEMBL25022) 0.52 5/20
SCHEMBL124423 SCHEMBL124423 0.50 5/20
Retinol Retinol (SCHEMBL3112) 1.00 4/20
Retinol Retinol (SCHEMBL3113) 1.00 4/20
Tretinoin Tretinoin (SCHEMBL3145) 1.00 4/20
Tretinoin Tretinoin (SCHEMBL3146) 1.00 4/20
Tretinoin Tretinoin (SCHEMBL3952) 1.00 4/20
Retinol Retinol (SCHEMBL15592) 1.00 4/20
Retinol Retinol (SCHEMBL15593) 1.00 4/20
Retinol Retinol (SCHEMBL17226) 1.00 4/20
Alitretinoin Alitretinoin (SCHEMBL18666) 1.00 4/20

Clinical trials — most relevant to SNCA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Ambroxol as a Disease-modifying Treatment in GBA-PD PHASE2COMPLETED
A Study to Evaluate Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Parkinson's Disease PHASE2NOT_YET_RECRUITING
Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia PHASE1/PHASE2NOT_YET_RECRUITING
A Clinical Study to Evaluate the Safety of MF1, a New Treatment for Parkinson's Disease-related Disorders (MF1 Study) PHASE1RECRUITING
First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD) PHASE1RECRUITING
Application of 18F-CP6A PET Imaging in Synucleinopathies EARLY_PHASE1NOT_YET_RECRUITING
The Effect of Immersion in Virtual Reality on Upper Limb Functionality in Subjects With Parkinson's Disease: Randomized Clinical Trial nanUNKNOWN
Age Dependents Benefits of Virtual Reality Rehabilitation nanCOMPLETED
Synuclein-One Study nanCOMPLETED
Gut Microbiota in the Progression of Alpha-synucleinopathies nanUNKNOWN
Gut Microbiota and Parkinson's Disease nanUNKNOWN
Biomarkers in Alzheimer's and Parkinson's Diseases for IA nanACTIVE_NOT_RECRUITING
Understanding Alpha-Synuclein Spread in Parkinson's Disease Through Blood Biomarkers and Neuroimaging nanNOT_YET_RECRUITING
DTI in Evaluation of Parkinsons Disease nanUNKNOWN
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort nanRECRUITING
Diagnosis of Parkinson´s Disease by Means of Submandibular Gland Needle Biopsy nanUNKNOWN
Exercise Neuroprotection in Parkinson's Disease nanRECRUITING
Aerobic Exercise and Brain Health in Parkinson's nanCOMPLETED
Oligomeric Alpha-synuclein in Multiple System Atrophy nanCOMPLETED
Natural History and Disease Progression Biomarkers of Multiple System Atrophy nanCOMPLETED
Biomarkers in Parkinsonian Syndromes nanUNKNOWN
Biomarker Analysis for GBA Associated Parkinson's Disease nanUNKNOWN
Natural History Study of Synucleinopathies nanRECRUITING
Efficacy of Cognitive Rehabilitation Using Virtual Reality and Computer-based Cognitive Stimulation on Cognitive Impairment Associated to Movement Disorders nanCOMPLETED
A Registered Cohort Study on α-Synucleinopathy nanRECRUITING
Establishing Alpha-synuclein RT-QuIC Assay as a Diagnostic Technique in REM Sleep Behaviour Disorder nanWITHDRAWN
Chinese PD-SNCA Registry nanRECRUITING
Effects of Probiotics on Peripheral Immunity in Parkinson's Disease nanUNKNOWN
Biological Markers in Parkinson's Disease nanCOMPLETED
Alpha-synuclein Rt-quic and Neurologic Symptoms in Persons With idiOpathic anosMiA nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a SNCA binder may also engage these)

ProteinNameSimilarity
P61144 1.000 P61144 →
P61139 1.000 P61139 →
P61146 1.000 P61146 →
P61142 1.000 P61142 →
P61140 1.000 P61140 →
P61145 1.000 P61145 →
P61141 1.000 P61141 →
P61143 1.000 P61143 →
O55042 1.000 O55042 →
Q3I5G7 1.000 Q3I5G7 →
P61138 1.000 P61138 →
P61147 1.000 P61147 →
Q91448 1.000 Q91448 →
Q3T0G8 1.000 Q3T0G8 →
P37379 1.000 P37379 →
Q63754 1.000 Q63754 →
P37377 1.000 P37377 →
Q2PFW6 0.997 Q2PFW6 →
Q16143 0.996 Q16143 →
P33567 0.994 P33567 →
Q63544 0.993 Q63544 →
O76070 0.993 O76070 →
Q91ZZ3 0.992 Q91ZZ3 →
Q9Z0F7 0.991 Q9Z0F7 →
Q9NZ50 0.991 Q9NZ50 →
B3EWG6 0.981 B3EWG6 →
Q46466 0.980 Q46466 →
B3EWG5 0.978 B3EWG5 →
B3EWG3 0.978 B3EWG3 →
Q6TMJ3 0.977 Q6TMJ3 →